Paula M. Hale

5.4k total citations · 4 hit papers
43 papers, 4.2k citations indexed

About

Paula M. Hale is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Paula M. Hale has authored 43 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Molecular Biology and 13 papers in Pharmacology. Recurrent topics in Paula M. Hale's work include Diabetes Treatment and Management (26 papers), Metabolism, Diabetes, and Cancer (18 papers) and Pharmacology and Obesity Treatment (12 papers). Paula M. Hale is often cited by papers focused on Diabetes Treatment and Management (26 papers), Metabolism, Diabetes, and Cancer (18 papers) and Pharmacology and Obesity Treatment (12 papers). Paula M. Hale collaborates with scholars based in United States, Denmark and Canada. Paula M. Hale's co-authors include Milan Zdravkovic, Bruce W. Bode, Robert R. Henry, Robert E. Ratner, Philip Raskin, Lawrence Blonde, John B. Buse, Pedro Alberto García-Hernández, Alan J. Garber and Priscilla Hollander and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Paula M. Hale

42 papers receiving 4.0k citations

Hit Papers

Liraglutide versus glimep... 2008 2026 2014 2020 2008 2009 2013 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
    2008 882 citations Alan J. Garber, Robert R. Henry et al. The Lancet profile →
  2. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
    2009 707 citations Bernard Zinman, John Gerich et al. Diabetes Care profile →
  3. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
    2013 610 citations Paula M. Hale et al. profile →
  4. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
    2020 431 citations Aaron S. Kelly, Margarita Barrientos‐Pérez et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paula M. Hale United States 19 3.4k 1.6k 1.4k 1.2k 708 43 4.2k
Salvatore Calanna Denmark 20 2.6k 0.8× 1.1k 0.7× 1.3k 0.9× 1.0k 0.9× 1.0k 1.4× 27 4.0k
Christine B. Jensen Denmark 22 2.5k 0.7× 1.2k 0.8× 1.8k 1.2× 898 0.7× 1.5k 2.2× 26 4.2k
Sue D. Pedersen Canada 21 3.0k 0.9× 1.3k 0.8× 1.5k 1.0× 980 0.8× 1.0k 1.4× 49 4.2k
Domenica Rubino United States 23 2.3k 0.7× 849 0.5× 1.6k 1.1× 567 0.5× 989 1.4× 60 3.4k
Marie Thi Dao Tran Denmark 6 1.5k 0.4× 599 0.4× 1.0k 0.7× 597 0.5× 792 1.1× 11 2.6k
Ole Kleist Jeppesen Denmark 10 2.2k 0.6× 1.0k 0.7× 931 0.6× 666 0.6× 528 0.7× 20 2.9k
Niels Zeuthen Denmark 6 1.6k 0.5× 655 0.4× 1.1k 0.8× 626 0.5× 811 1.1× 17 2.7k
John Gerich United States 10 2.5k 0.7× 941 0.6× 281 0.2× 937 0.8× 330 0.5× 11 3.1k
Nadia N. Ahmad United States 12 1.5k 0.4× 490 0.3× 1.1k 0.8× 621 0.5× 1.0k 1.4× 26 2.7k
Mathijs C. Bunck United States 10 1.6k 0.5× 458 0.3× 1.0k 0.7× 578 0.5× 968 1.4× 21 2.7k

Countries citing papers authored by Paula M. Hale

Since Specialization
Citations

This map shows the geographic impact of Paula M. Hale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula M. Hale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula M. Hale more than expected).

Fields of papers citing papers by Paula M. Hale

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula M. Hale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula M. Hale. The network helps show where Paula M. Hale may publish in the future.

Co-authorship network of co-authors of Paula M. Hale

This figure shows the co-authorship network connecting the top 25 collaborators of Paula M. Hale. A scholar is included among the top collaborators of Paula M. Hale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula M. Hale. Paula M. Hale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Name, Michelle Van, Björg Ásbjörnsdóttir, Marília Brito Gomes, et al.. (2025). Pharmacokinetic Properties of Once‐Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes. Pediatric Diabetes. 2025(1). 1 indexed citations
2.
Baker, Jennifer L., Carine de Beaufort, Ruth M. Belin, et al.. (2024). Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings. Pediatric Obesity. 19(11). e13161–e13161. 2 indexed citations
3.
Bramante, Carolyn T., Eric M. Bomberg, Claudia K. Fox, et al.. (2023). Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial. Pediatric Obesity. 18(9). e13061–e13061. 15 indexed citations
4.
Petri, Kristin C. Carlsson, Paula M. Hale, Dan Hesse, Naveen Rathor, & Lucy D. Mastrandrea. (2021). Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity. Pediatric Obesity. 16(10). e12799–e12799. 11 indexed citations
5.
Tamborlane, William V., Margarita Barrientos‐Pérez, Udi Fainberg, et al.. (2019). Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal of Medicine. 381(7). 637–646. 222 indexed citations
6.
7.
8.
Falloon, Garry, et al.. (2016). Planning and implementing coding in the junior classroom for competency and thinking-skill development. set Research Information for Teachers. 2016(1). 8–16. 4 indexed citations
9.
Klein, David J., et al.. (2014). Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Technology & Therapeutics. 16(10). 679–687. 85 indexed citations
10.
Zinman, Bernard, J. E. Gerich, John B. Buse, et al.. (2010). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)). Diabetes Care. 33(3). 240 indexed citations
11.
12.
Zinman, Bernard, John Gerich, John B. Buse, et al.. (2009). Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). Diabetes Care. 32(7). 1224–1230. 707 indexed citations breakdown →
13.
Garber, Alan J., Robert R. Henry, Robert E. Ratner, et al.. (2008). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The Lancet. 373(9662). 473–481. 882 indexed citations breakdown →
14.
Raskin, Philip, Janet B. McGill, Mohammed Saad, et al.. (2004). Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone. Diabetic Medicine. 21(4). 329–335. 24 indexed citations
15.
Jovanovič, Lois, et al.. (2003). Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Research and Clinical Practice. 63(2). 127–134. 60 indexed citations
16.
Lipman, Terri H., et al.. (2002). Assessment of Growth and Immunologic Function in HIV-Infected and Exposed Children. Journal of the Association of Nurses in AIDS Care. 13(3). 37–45. 2 indexed citations
17.
Lipman, Terri H., et al.. (2000). Risk Factors for Cardiovascular Disease in Children with Type I Diabetes. Nursing Research. 49(3). 160–166. 18 indexed citations
18.
Lipman, Terri H., et al.. (2000). Assessment of growth by primary health care providers. Journal of Pediatric Health Care. 14(4). 166–171. 17 indexed citations
19.
Anggiansah, Angela, et al.. (1993). Significantly reduced acid detection at 10 centimeters compared to 5 centimeters above lower esophageal sphincter in patients with acid reflux.. PubMed. 88(6). 842–6. 43 indexed citations
20.
Foster, Carol M., Nancy J. Hopwood, Jeanne M. Hassing, et al.. (1989). Nocturnal Serum Growth Hormone Concentration is not Augmented by Short-Term Testosterone Infusion in Pubertal Boys. Pediatric Research. 26(4). 320–324. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Salvatore Calanna Breakdown of academic impact, for papers by Christine B. Jensen Breakdown of academic impact, for papers by Sue D. Pedersen Breakdown of academic impact, for papers by Domenica Rubino Breakdown of academic impact, for papers by Marie Thi Dao Tran Breakdown of academic impact, for papers by Ole Kleist Jeppesen Breakdown of academic impact, for papers by Niels Zeuthen Breakdown of academic impact, for papers by John Gerich Breakdown of academic impact, for papers by Nadia N. Ahmad Breakdown of academic impact, for papers by Mathijs C. Bunck
Rankless by CCL
2026